Alembic Ltd reported a 12% drop in standalone profit for FY26 to ₹124.54 crore, mainly due to higher taxes. Real estate revenue rose to ₹185.35 crore, with key projects fully sold. The API segment faces competition.
Alembic Ltd Reports FY26 Financials: Real Estate Drives Revenue Amidst Profit Dip
Standalone profit after tax for Alembic Ltd for the financial year ended March 31, 2026, declined to ₹124.54 crore from ₹141.95 crore in the previous fiscal year. Standalone revenue from operations for FY26 increased to ₹231.93 crore, up from ₹214.36 crore in FY25. Reader Takeaway: Real estate revenue growth masks API segment challenges and higher tax burden. ## What just happened Alembic Ltd announced its financial results for the fiscal year ending March 31, 2026. The company's standalone profit after tax saw a decrease of approximately 12.27%, falling to ₹124.54 crore. This decline was primarily attributed to a significant increase in tax expenses, which rose to ₹22.35 crore from ₹10.04 crore in the prior year. However, standalone revenue from operations showed a positive trend, growing by about 8.2% to ₹231.93 crore in FY26, compared to ₹214.36 crore in FY25. On a consolidated basis, revenue from operations stood at ₹239.99 crore, with total profit after tax and share of associates reported at ₹317.38 crore. ## Why this matters The dip in profitability, despite revenue growth, highlights the impact of higher taxes on the bottom line. Investors will be keen to understand the sustainability of revenue growth and the factors influencing profitability. The performance of the real estate segment offers a positive outlook, while the API business presents ongoing challenges. ## The backstory Alembic Ltd has been diversifying its business interests. While historically known for its pharmaceutical business (API), the company has increasingly focused on its real estate ventures. The API segment, however, faces headwinds from a limited product portfolio and intense market competition, prompting the company to focus on operational efficiencies. ## What changes now With the announcement of the dividend recommendation of ₹2.40 per equity share (120%), the company signals its intent to reward shareholders. The appointment of Mr. Udit Amin as Managing Director and Mrs. Malika Amin's transition to a Non-Executive role suggest a planned leadership transition. ## Risks to watch The API segment's outlook remains a concern due to high competition and product constraints, potentially impacting its long-term viability. Additionally, the company faces a contingent liability related to an electricity duty dispute, with ₹20.52 crore provided and ₹35 crore deposited with the Supreme Court. ## Peer comparison While specific peer financial data for FY26 is not immediately available, the real estate segment's success with projects like 'VEDA-II' and 'The Gardens' suggests strong execution in that vertical. The challenges in the API segment are common across many smaller players in the Indian pharmaceutical industry facing pricing pressures and regulatory scrutiny. ## Context metrics (time-bound) - **Standalone Revenue FY26:** ₹231.93 crore (vs. ₹214.36 crore FY25) - **Standalone PAT FY26:** ₹124.54 crore (vs. ₹141.95 crore FY25) - **Consolidated Revenue FY26:** ₹239.99 crore - **Dividend Proposed:** ₹2.40 per equity share (120%) ## What to track next Investors should closely monitor the performance of the real estate segment, particularly lease commitments for the new commercial building. Developments regarding the API business, including strategies for yield improvement and portfolio expansion, will be crucial. The outcome of the electricity duty dispute also remains a point to watch.
